Long-term efficacy and safety of netakimab in patients with moderate-to-severe psoriasis. Results of phase II open-label extension clinical study BCD-085-2-ext
Netakimabis original monoclonal antibody against IL-17. This article outlines the key results of a phase II open-label extension trial of netakimab 80 mg and 120 mg in patients with moderate-to-severe psoriasis.The main aim of the trial is to estimate efficacy, safety and immunogenicity of long-term...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
State Scientific Center of Dermatovenereology and Cosmetology
2019-10-01
|
| Series: | Vestnik Dermatologii i Venerologii |
| Subjects: | |
| Online Access: | https://www.vestnikdv.ru/jour/article/view/499 |